Opus Genetics News Today

Harrow announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company?s Board of Directors, effective immediately. Harrow?s Board now consists of six members. Dr. Adrienne...

Triangle Venture Day, hosted at Apella by Alexandria at the Alexandria Center for Advanced Technologies campus, proved to be one of promise of the Triangle’s growing innovation ecosystem, optimism for high-impact science, and enthusiasm for local collaboration.

The North Carolina Biotechnology Center awarded 31 grants and loans totaling $2,764,811 to universities, life sciences companies and non-profit organizations in the fourth quarter of its fiscal year. Here are the details.

The North Carolina Biotechnology Center awarded 31 grants and loans totaling $2,764,811 to universities, life sciences companies and non-profit organizations in the fourth quarter of its fiscal year.The awards, made in April, May and June, will support bioscience research, technology commercialization and entrepreneurship throughout North Carolina. The funding will also help universities and companies attract follow-on funding from other sources.

Half had paid staff or executives with pharma and medical device conflicts of interest

Opus Genetics, a Research Triangle Park drug development startup focused on inherited diseases of the retina, has raised an additional $4.5 million in funding from investors.

The years cohort of six recipients include a journalist, an astrophysicist, and Nobel Prize winners.

Jean Bennett’s profile on The Conversation

Penn will award Menzel, a Tony award-winning actress, an honorary Doctor of Arts at the ceremony, according to an announcement from Vice President and University Secretary Medha Narvekar. 

RTP gene therapy startup Opus Genetics has acquired the rights to two pre-clinical product candidates to treat inherited retinal diseases from New Jersey biopharm company Iveric Bio.